Rocket Lab Corp (RKLB) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers Rocket Lab USA, Inc.'s quarterly report on Form 10-Q for the period ended June 30, 2024. Rocket Lab is an end-to-end space company providing launch services (Electron and developing Neutron vehicles) and space systems (spacecraft components, manufacturing, and mission operations). The company operates two reportable segments: Launch Services and Space Systems.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $106.3 million | $62.0 million | $199.0 million | $116.9 million |
| Gross Profit | $27.2 million | $14.6 million | $51.3 million | $21.0 million |
| Gross Margin | 25.6% | 23.5% | 25.8% | 17.9% |
| Operating Loss | $(43.3) million | $(45.2) million | $(86.4) million | $(91.2) million |
| Net Loss | $(41.6) million | $(45.9) million | $(85.9) million | $(91.5) million |
| Cash & Equivalents | $340.9 million (as of June 30, 2024) | |||
| Marketable Securities | ||||
| Total Debt (Principal) | $419.2 million (Convertible Notes + Trinity Loan) | |||
| Backlog | $1,066.6 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 71% year-over-year in Q2 and 70% year-over-year for the six months ended June 30, 2024. This was driven by a 94% increase in Space Systems revenue (due to spacecraft manufacturing growth) and a 31% increase in Launch Services revenue (due to higher launch cadence: 4 launches in Q2 2024 vs. 3 in Q2 2023).
- Margin Expansion: Gross margin improved to 25.6% in Q2 2024 from 23.5% in Q2 2023, and 25.8% YTD 2024 from 17.9% YTD 2023. Cost of revenue as a percentage of revenue decreased to 74.2% YTD 2024 from 82.1% YTD 2023.
- Operating Expenses: R&D expenses increased 29% in Q2 and 43% YTD, primarily due to Neutron development progress and hiring. SG&A expenses increased modestly (6% in Q2, 4% YTD) to support revenue growth.
- Capital Structure: In February 2024, the company issued $355 million in 4.250% Convertible Senior Notes due 2029. Proceeds were used to repay existing debt and fund operations. The company also purchased capped call transactions for $43.2 million to offset potential dilution.
Guidance, Outlook, and Risks
- Neutron Development: The company successfully completed the first hot fire of the Archimedes engine for the Neutron launch vehicle. The first flight is now scheduled for no earlier than mid-2025.
- Recent Contracts: Announced a ten-launch agreement with Synspective (largest Electron deal to date) and a preliminary memorandum for up to $23.9 million in funding under the CHIPS and Science Act, plus up to $25.5 million in state incentives from New Mexico.
- Liquidity: Management believes existing cash, cash equivalents, and customer payments are sufficient to meet working capital and capital expenditure needs for at least the next 12 months.
- Risks: Key risks include the ability to operate Electron at anticipated rates, delays in Neutron development, supply chain disruptions, reliance on key customers (MDA Corporation accounted for 26% of revenue YTD 2024), and the need for additional capital if growth accelerates faster than cash generation.
Investor Verification Checklist
- Neutron Timeline: Verify the feasibility of the mid-2025 first flight target for the Neutron vehicle, given the complexity of medium-lift development.
- Launch Cadence: Monitor the ability to sustain the increased launch rate (8 launches YTD 2024 vs. 6 YTD 2023) without impacting margins or causing delays.
- Debt Service: Review the impact of the new $355 million convertible notes and the Trinity Loan Agreement on future interest expenses and cash flow.
- Customer Concentration: Assess the risk associated with MDA Corporation representing 26% of YTD revenue and the potential impact of any contract modifications or cancellations.
- Government Funding: Confirm the finalization and disbursement schedule of the CHIPS and Science Act funding and New Mexico state incentives.